Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042339 | 1.00 | LDHA (0.52) | LDHAPTGS2AKR1C3AKR1C2CYP1A2 | |
| SCHEMBL7037842 | 1.00 | LDHA (0.52) | LDHAPTGS2AKR1C3AKR1C2CYP1A2 | |
| SCHEMBL30057651 | 0.94 | ALOX5 (0.54) | LDHAPTGS2AKR1C3AKR1C2CYP1A2 | |
| SCHEMBL11664001 | 0.87 | ALDH1A1 (0.42) | LDHAPTGS2AKR1C3AKR1C2CYP1A2 | |
| SCHEMBL2879870 | 0.84 | CA1 (0.53) | CYP1A2CA1CA2NPSR1ACP3 | |
| SCHEMBL1354444 | 0.84 | CA1 (0.53) | CYP1A2CA1CA2NPSR1ACP3 | |
| SCHEMBL1115061 | 0.84 | CA1 (0.53) | CYP1A2CA1CA2NPSR1ACP3 | |
| SCHEMBL5966755 | 0.84 | AKR1C3 (0.69) | PTGS2AKR1C3AKR1C2CYP1A2PTGS1 | |
| SCHEMBL5966760 | 0.84 | AKR1C3 (0.69) | PTGS2AKR1C3AKR1C2CYP1A2PTGS1 | |
| SCHEMBL13527786 | 0.82 | HSD17B10 (0.61) | CYP1A2PTGS1GRM8GRM6GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-4233456-A | Process for the manufacture of optically active, optionally substituted 2-amino-2-phenylacetic acid | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1980-11-11 | — | — | US | claimed |
| US-4185116-A | L- and DL- Phenylglycines to treat diseases or conditions attributable to reduced carbohydrate metabolism | PFIZER INC. (US) | 1980-01-22 | — | — | US | claimed |
| US-4172846-A | Process for separating a mixture of an optically active phenylglycine amide and an optically active phenylglycine | STAMICARBON, B.V. (NL) | 1979-10-30 | — | — | US | claimed |
| US-4148920-A | CARDIOVASCULAR DISORDERS, DIABETICS, OBESITY | PFIZER INC. (US) | 1979-04-10 | — | — | US | claimed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| WO-2023081764-A1 | HEXADEPSIPEPTIDE COMPOUNDS AND METHODS OF USING THE SAME | ZYMERGEN INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11415887-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11187980-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-11-30 | — | — | US | disclosed |
| US-3978223-A | UREIDOACETAMIDO-PENICILLINS FOR TREATING BACTERIAL INFECTIONS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-31 | — | — | US | disclosed |
| US-3974140-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3959258-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
| US-3939149-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3936442-A | ANTIBIOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-03 | — | — | US | disclosed |
| US-3933795-A | Ureidoacetamido-penicillins | Konig, Hans-Bodo (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | LDHA 2079/4885PTGS2 3378/4885AKR1C3 4142/4885 |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | GRIN3A, GRIN3B, GRIN1 | LDHA 3923/4885PTGS2 1453/4885AKR1C3 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.